Immunovant, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Departure of Chief Technology Officer
On November 4, 2026, Jay Stout, a current named executive officer of the Company, notified the Company of his intention to retire from his position as Chief Technology Officer of the Company, effective on or around December 4, 2026. Dr. Stout’s decision was not the result of any disagreement with us on any matter relating to the Company’s operations, policies, or practices. The Company anticipates entering into a Separation Agreement with Dr. Stout that will include a standard release of claims in favor of the Company and include terms for certain consulting services to be provided by Dr. Stout to the Company to support the transition of his responsibilities.
Insider Trading Arrangements
During the three months ended September 30, 2026, none of our directors or Section 16 reporting officers adopted, modified orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC’s Regulation S-K) except as disclosed below.
| Name and Title | Action | Date | Duration of Trading Arrangement | Rule 10b5-1 Trading Arrangement (Y/N)(1) | Number of Shares of Common Stock to be Sold |
|---|---|---|---|---|---|
| Christopher Van Tuyl, Chief Legal Officer | Adoption | August 21, 2026 | December 17, 2026 – August 20, 2027 | Y | 34,408 |
| Tiago Girao, Chief Financial Officer | Adoption | August 21, 2026 | November 20, 2026 – December 31, 2027 | Y | 100,000 |
(1) Contract, instruction, or written plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.